Please provide your email address to receive an email when new articles are posted on . There were several important FDA approvals for GI conditions over the past year, including the first treatment ...

Ironwood Pharmaceuticals has established itself as a leader in the gastrointestinal healthcare space with its innovative products and pipeline development. The demand for LINZESS, a therapy for ...

Allergan today disclosed deals that will expand its gastrointestinal (GI) pipeline with four potential treatments focused on the microbiome, as well as broaden its R&D portfolio through an option to ...

– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 – Inflammatory bowel disease ...